胰腺癌外科治疗单中心10年临床经验分析  

Surgical therapy of pancreatic cancer for 10-year experience from single institute

作　　者：卫文栋[1] 孙家邦[1] 李非[1] 刘爽[1] 

机构地区：[1]首都医科大学宣武医院普通外科,北京100053

出　　处：《中国现代普通外科进展》2012年第5期352-355,共4页Chinese Journal of Current Advances in General Surgery

摘　　要：目的:探讨胰腺癌外科治疗的疗效。方法:回顾性分析我院普通外科2000—2010年经病理学检查或手术确诊的130例胰腺癌患者的临床资料。结果:130例胰腺癌患者中,首发症状前3位依次为腹痛、黄疸和消瘦,平均就诊时间91.99 d。根治性切除27例(20.77%),姑息性短路手术98例(75.38%)。Ⅰ～Ⅱ期患者手术切除率为85.19%,Ⅲ～Ⅳ期为3.88%。根治性手术患者术后中位生存时间为20月,而捷径手术患者的术后中位生存时间为5月。结论:手术是目前治疗胰腺癌的唯一有效手段,Ⅰ～Ⅱ期患者手术切除率高,但预后并不令人满意。应加强胰腺癌的综合治疗,特别是对失去手术切除机会的中晚期患者的综合治疗。Objective： To evaluate the efficacy of surgical therapy in pancreatic cancer. Meth- ods： Retrospective analysis was applied in the clinic feature of 130 patients with pancreatic cancer who were treated in our hospital during the past 10 years. Results： The three most common prima- ry symptoms of patients with pancreatic cancer were abdominal pain, jaundice and weight loss in turn. It would need average 3 months to get an identified diagnosis. The radical resection rate in stage I and II was 85.19%, in stage III and IV it was only 3.88%. Radical resection was performed to 27 patients, the median survival time was 20 months, while by-pass operation was performed to 96 cases, the median survival time was only 5 months. Conclusion： Surgical resection is still the only effective therapeutic method for pancreatic cancer. Long-term survival is not so satisfied even in stage I and II patients among whom resection incidence is relatively higher. So adjuvant therapy is necessary, especially in unresectable advanced cases.

关 键 词：胰腺肿瘤·外科治疗·预后 

分 类 号：R735.9[医药卫生—肿瘤]